Kazia Forms Licensing Agreement with QIMR Berghofer
Kazia Therapeutics Limited (NASDAQ: KZIA), a company dedicated to cancer drug development, is excited to announce a major licensing deal with QIMR Berghofer Medical Research Institute, one of Australia’s premier cancer research institutes. This agreement provides Kazia exclusive rights to specific intellectual property related to innovative combination therapies that pair PI3K inhibitor drugs with immunotherapy or PARP inhibitors.
Key Aspects of the Partnership
Through this licensing agreement, Kazia has obtained a worldwide license that is sub-licensable and royalty-bearing for the development of drug candidates within the PI3K inhibitor category, especially when used alongside immunotherapy or PARP inhibitors. This is particularly relevant for Kazia's leading candidate, paxalisib, which belongs to this drug class and positions the company to enhance its research and clinical development strategies significantly.
Success of the Collaboration
This exclusive license emerges from a productive partnership that began between Kazia and QIMR Berghofer in late 2022. Their collaboration has successfully led to the filing of important patents, especially regarding the application of paxalisib as an immune modulator for treating various cancers, including breast cancer.
Thoughts from Kazia's CEO on the License Agreement
Dr. John Friend, CEO of Kazia, shared his excitement about the agreement, saying, "This is an exciting evolution in our partnership with QIMR Berghofer and an important milestone for Kazia's development of paxalisib alongside our commercial portfolio as we secure the license for a significant cancer immunotherapy pathway. We’re thrilled to have obtained potential intellectual property rights around PI3K inhibitors, empowering us to explore innovative cancer treatments, specifically in solid tumors like breast cancer."
Praise from QIMR Berghofer
Professor Fabienne Mackay, Director and CEO of QIMR Berghofer, noted the successful collaboration, stating, "We are pleased to enter this exclusive license agreement with Kazia after a fruitful two-year research partnership. We look forward to advancing clinical developments for PI3K inhibitor drugs, including paxalisib, to provide meaningful benefits to cancer patients."
Research Efforts
Kazia's ongoing preclinical studies at QIMR Berghofer revolve around paxalisib regarding solid tumors. This research is led by Professor Sudha Rao, a cancer biology expert who focuses on studying how paxalisib interacts with other therapies in cases of Triple Negative Breast Cancer and other advanced breast cancers.
Promising Preclinical Findings
Initial preclinical results have been encouraging, indicating that combining paxalisib with checkpoint inhibitors significantly enhances the immune response against tumors. These revelations underscore paxalisib's potential to bolster the effectiveness of immunotherapy, particularly in challenging cancers like breast cancer. More detailed results from these studies are anticipated to be shared at upcoming scientific conferences in 2025.
Looking Ahead
As Professor Rao highlighted, "The immune system plays a vital role in fighting cancer. We need treatments that not only target tumor cells but also strengthen immunotherapy against metastatic cancers. Paxalisib stands out as a notable PI3K inhibitor, showing it can diminish primary tumor sizes while invigorating the immune response in patients. We’re eager to share more preliminary findings on paxalisib's role in treating breast cancer soon."
Overview of Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA) is leading efforts in oncology-focused drug development. Based in Sydney, the company’s primary product, paxalisib, targets multiple brain cancers via a well-studied pathway - the PI3K/Akt/mTOR pathway. Licensed from Genentech in late 2016, paxalisib has undergone several clinical trials that demonstrate its potential.
The company is actively conducting trials involving paxalisib for various conditions, including glioblastoma, where recent studies have noted promising clinical responses. A pivotal study has been wrapped up, with plans to present data at an upcoming major medical conference.
Regulatory Status
Paxalisib received Orphan Drug Designation from the FDA for glioblastoma in early 2018, later receiving Fast Track Designation for additional indications related to brain metastases and pediatric cancers. The company continues to build on its achievements with new trials and partnerships.
Final Thoughts
Kazia is committed not just to advancing treatments like paxalisib but also to developing EVT801, a small molecule that targets VEGFR3, providing hope for a wide array of cancer types. With promising preclinical results already in hand, Kazia plans to share more updates in the coming years as they continue to push their clinical research forward.
Frequently Asked Questions
What is the significance of Kazia's licensing agreement with QIMR Berghofer?
The licensing agreement gives Kazia the ability to develop innovative combination therapies that utilize PI3K inhibitors, broadening its oncology drug portfolio.
What are the main focuses of Kazia Therapeutics?
Kazia is focused on creating drugs for various cancer types, mainly through its lead candidate, paxalisib, targeting brain cancers.
What research is being conducted at QIMR Berghofer?
The research centers on investigating paxalisib's effectiveness in solid tumors such as breast cancer, with contributions from leading experts.
What is paxalisib?
Paxalisib is an investigational PI3K inhibitor designed to penetrate the brain and is currently being evaluated for its effectiveness against different forms of brain cancer.
How is Kazia positioned for future growth?
Kazia is looking into new therapeutic paths and has received favorable FDA designations, indicating strong potential for its investigational drugs.
